On July 28, MEDBOT-B declined 5.03% in regular trading, trading at HK$20.4/share, with turnover of approximately HK$71.54 million. The sell-off follows sharp rallies of over 10% on July 23 and approximately 7% on July 27, both driven by the company's first-ever half-year profit announcement.

Market analysis indicates the stock's price-to-sales ratio stands at approximately 35x, significantly above global peers such as Medtronic and Stryker, creating elevated profit-taking pressure at current levels. The company announced on July 22 that it expects net profit of RMB 28 million to RMB 40 million for H1, reversing a net loss of RMB 115 million in the prior-year period. Revenue surged 200%-230% year-over-year, driven by its Toumai surgical robot, with overseas revenue growing over 450%. Gross margin improved by more than 15 percentage points.

Within the Health Care Equipment sector, weakness was broad-based, with Lifetech Scientific down 6.62%, MicroPort Scientific down 1.49%, and TH Medical down 1.99%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)